A new study finds an association between complement factor H (CFH), high-temperature requirement A-1 (HTRA1), vascular endothelial growth factor (VEGF), and pigment epithelium-derived factor (PEDF) genotypes and response to treatment with photodynamic therapy (PDT) for age-related macular degeneration (AMD) in a Japanese population. Studies...

A new study finds that among patients with wet AMD those with higher risk genotypes response better to Lucentis (ranibizumab) therapy than patients with lower risk genotypes. Epidemiological and association studies have shown that both genetic and environmental factors play a major role in the development of AMD. Association studies have...

Age-related macular degeneration (AMD) has a complex etiology arising from genetic and environmental influences. This past decade have seen several genes associated with the disease. Variants in five genes have been confirmed to play a major role. It is hoped that such research will define the genetic biomarker spectrum to allow treatment...

Exudative AMD patients with the compliment factor H (CFH Y402H) high risk genotype (CC) received approximately one more Lucentis injection over a 9 month follow-up period than persons who do not have the high risk genotype. Genetic studies have made advancements in establishing the molecular cause of AMD. Two genes that seem to greatly...